BeyondSpring, Inc.

As of August 13, 2025, BeyondSpring, Inc. is considered overvalued with negative valuation ratios and a 1-year return of -19.44%, significantly underperforming compared to the S&P 500's gain of 17.14%.

As of December 29, 2021, BeyondSpring, Inc. is considered overvalued and has been downgraded to "risky" due to negative financial metrics, including a P/E ratio of -15.46 and unfavorable comparisons to peers, despite a stock return of 8.30% that lags behind the S&P 500's 10.26%.

As of June 9, 2025, the technical trend is mildly bullish, supported by a bullish weekly MACD and Bollinger Bands, despite some bearish signals in daily moving averages and a lack of momentum confirmation from the RSI.

As of March 2022, the management team of BeyondSpring, Inc. includes Dr. Huang Lan (Chairman, CEO, Co-Founder) and Dr. Ramon Mohanlal (Chief Medical Officer, EVP of Research and Development). The Board of Directors also features independent directors such as Mr. Patrick Fabbio and Dr. Daniel Zabrowski.

BeyondSpring, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology cancer therapies, with a market cap of approximately $137.08 million and a net profit of -$3 million as of March 2025. The company operates in the Pharmaceuticals & Biotechnology industry and has a debt equity ratio of 0.29.

As of Jun 18, BeyondSpring, Inc. has a market capitalization of 137.08 million and reported net sales of 1.02 million with a net profit of -53.34 million over the latest four quarters. Shareholder's funds are at -32.90 million, and total assets are 34.31 million as of Dec 24.